A case of unilateral recurrent cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies

Liying Guo; Ho Jun Yun; Xiaomu Tan; Xiaokun Geng; Yuchuan Ding

doi:10.4103/bc.bc_30_22

CASE REPORT

Year : 2022 | Volume : 8 | Issue : 2 | Page : 102-107

A case of unilateral recurrent cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies

Liying Guo¹, Ho Jun Yun², Xiaomu Tan¹, Xiaokun Geng³, Yuchuan Ding²
¹ Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
² Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA
³ Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA; Luhe Institute of Neuroscience, Capital Medical University, Beijing, China

Date of Submission	01-Jun-2022
Date of Decision	04-Jun-2022
Date of Acceptance	06-Jun-2022
Date of Web Publication	30-Jun-2022

Correspondence Address:
Xiaokun Geng
Department of Neurology, Stroke Center, Beijing Luhe Hospital, Capital Medical University, No. 82 Xinhua Southroad, Tongzhou District, Beijing 101149

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/bc.bc_30_22

Abstract

Myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) is an independent inflammatory demyelinating disease. A rare phenotype of MOGAD is cerebral cortical encephalitis (CCE). This case report presents unilateral recurrent cerebral cortical encephalitis (CCE) with positive anti-MOG antibodies from a 55 year old man who was admitted with headache, fever and aphasia. This case highlights the findings of hyperintense lesions in the cortex of the right temporal gyrus with slight swelling on T2 FLAIR and anti MOG antibodies in serum (1:20) and CSF (1:80) when the patient presented again to hospital after the initial improvement with IVIG and glucocorticoids. In addition, the patient was found to have atrophy of the whole brain, especially the right temporal lobe, after becoming symptom-free with glucocorticoids. In summary, anti-MOG-associated CCE can be diagnosed with headache, fever, and seizures associated with the presence of anti-MOG antibodies. Unilateral CCE is a special clinical feature of MOGAD and cerebral atrophy can be found. Steroid therapy remains to be the standard treatment.

Keywords: Atrophy, cerebral cortical encephalitis, myelin oligodendrocyte glycoprotein, recurrent

How to cite this article:
Guo L, Yun HJ, Tan X, Geng X, Ding Y. A case of unilateral recurrent cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies. Brain Circ 2022;8:102-7

How to cite this URL:
Guo L, Yun HJ, Tan X, Geng X, Ding Y. A case of unilateral recurrent cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies. Brain Circ [serial online] 2022 [cited 2023 Jun 6];8:102-7. Available from: http://www.braincirculation.org/text.asp?2022/8/2/102/349400

Introduction

Myelin oligodendrocyte glycoprotein (MOG) is a protein specifically expressed on the surface of myelin sheaths and oligodendrocytes in the central nervous system, which distinguishes from the classic multiple sclerosis and AQP4-immunoglobulin G (IgG)-positive neuromyelitis optica spectrum disorders.^[1] MOG antibody (MOG-ab)-associated disease (MOGAD) has a range of various clinical phenotypes and radiological features, including optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), and brainstem syndrome.^[2] In addition, encephalitis is an important phenotype with cortical lesions most frequently observed.^[3] Unilateral cerebral cortical encephalitis (CCE) is a rare phenotype of MOGAD which was first described by Ogawa et al.^[4] Previous studies show that patients with MOGAD are highly sensitive to corticosteroids and can achieve complete symptom remission.^[4],[5],[6] This case report presents ipsilateral recurrent unilateral CCE with positive anti-MOG antibodies.

Case Report

A 55-year-old man presented with headache and aphasia. His headache suddenly occurred 2 days in prior in the right temporal, parietal, and occipital lobes and persisted with no regression. The headache was associated with a fever of 37.5°C (99.5°F) that was controlled with oral medications. His aphasia occurred 1 day in prior and lasted for an hour with complete recovery subsequently. His aphasia recurred 3 h before his presentation to the hospital without remission. On admission, his vital signs were a temperature of 36.8°C, a heart rate of 66 beats per minute, and a blood pressure of 126/84 mmHg. He had anomic aphasia, hypoesthesia in the left limb, and positive Babinski sign on the left. There was no meningeal irritation sign, and the patient was alert. Complete blood count and other serum values were normal. Lumbar puncture revealed an opening pressure of 19 cm H2O, white blood cell (WBC) of 2/cmm, elevated protein (0.48 g/L), and the absence of oligoclonal bands. Intrathecal IgG synthesis rate of 24 h was normal. Serum and cerebrospinal fluid (CSF) for anti-Hu, Yo, Ri, N-methyl-D-aspartate receptor (NMDAR), glutamic acid decarboxylase (GAD), voltage-gated potassium channel (VGKC), and anti-aquaporin-4 antibodies were negative as well as herpes virus antibodies. Brain magnetic resonance imaging (MRI) showed T2-fluid-attenuated inversion recovery (FLAIR) hyperintensity and swelling of the right temporal and occipital cortex and adjacent sulci [Figure 1]a, [Figure 1]b, [Figure 1]c, [Figure 1]d without obvious contrast enhancement [Figure 1]e and [Figure 1]f. Routine electroencephalogram showed persistently slow waves in the right hemisphere but showed epileptic discharge during the interictal state.

Figure 1: Brain MRI with anti-MOG-associated cerebral cortical encephalitis after the first. Axial T2-FLAIR images showed hyperintensity and swelling of the cortex in the right temporal, parietal, and occipital lobes (a-d) without gadolinium contrast enhancement (e and f). Lesions indicated by white arrowheads. MRI: Magnetic resonance imaging, T2-FLAIR: T2-weighted fluid-attenuated inversion recovery, MOG: Myelin oligodendrocyte glycoprotein

Click here to view

On hospital day 3, he developed involuntary movement of the left hand and generalized tonic seizure for several minutes with unconsciousness, limb jerking, and left eye gaze. Diazepam was added for seizure control, and the patient was found to have a mild left hemiparesis subsequently. On hospital day 5, he developed an involuntary twitch of the right corner of the mouth. Intravenous immunoglobulin (0.4g/kg·d for 5 days) was started for possible autoimmune encephalitis and his left hemiparesis was improved slightly. In addition, high-dose glucocorticoid was given (methylprednisolone 1 g/day for 5 days), followed by a gradual reduction to oral prednisolone. The patient improved rapidly and was able to be discharged without residual symptoms. His prednisone was gradually reduced and stopped over 3 months. A repeat MRI revealed full resolution from the initial abnormalities.

The patient presented 4 months later to the hospital with paroxysmal dizziness for a week. The patient had gradual memory impairment and slow responsiveness ever since her discharge from the previous hospital admission. Lumbar puncture showed an opening pressure of 13.5 cm H2O and WBC of 16/cmm. Serum and CSF showed negative results for anti-CV2/CRMP5,-PNMA2,-Ri,-Yo,-Hu,-Amphiphysin, NMDA-R-IgG, CASPR2-IgG, AMPA1-R-IgG, AMPA2-R-IgG, LGI1-IgG, and GABAB-R-IgG antibodies. Anti-MOG antibodies were positive both in serum (1:20) and in the CSF (1:80). Visually evoked potentials demonstrated impaired optic pathway conduction bilaterally, as manifested by a prolonged latency of bilateral P100 wave. Brain MRI showed hyperintense lesions in the cortex of the right temporal gyrus with slight swelling on T2-FLAIR [Figure 2]a, [Figure 2]b, [Figure 2]c, and the lesions became larger 5 days later [Figure 2]d, [Figure 2]e, [Figure 2]f. Furthermore, there was slight partial marginal enhancement with contrast. There was no abnormality from optic MRI.

Figure 2: Brain MRI after the second admission showed hyperintense lesions in the right temporal gyrus with slight swelling on T2-FLAIR (a-c). The lesions became larger 5 days later (d-f). The patient was discharged 17 days later with improved symptoms; MRI still showed abnormal signals in the right temporal gyrus on T2-FLAIR (g-i). MRI: Magnetic resonance imaging, T2-FLAIR: T2-weighted fluid-attenuated inversion recovery

Click here to view

The patient was diagnosed with MOG antibody-positive CCE. High-dose glucocorticoids (1,000 mg/d) were administered. A repeat MRI study noted abnormal signals in the right temporal lobe on T2-FLAIR [Figure 2]g, [Figure 2]h, [Figure 2]i. After 12 days of treatment, the patient became free from the symptoms, and glucocorticoids were gradually tapered; he was subsequently discharged from the hospital. Oral prednisolone (60 mg/d) was started 11 days after and eventually tapered to 5 mg/d. Brain MRI was repeated 5 months after and showed atrophy of the whole brain, especially the right temporal lobe, and no residual hyperintense lesion [Figure 3]. Oral prednisone was continued for another 8 months, and the patient reported no new complaints. Repeated brain MRI has no significant change compared to the previous ones during follow-up period.

Figure 3: Compared to the initial brain MRI during the first admission (a-d), MRI performed 14 months later during follow-up (e-h) showed cortical atrophy, especially in the right temporal lobe, and dilation of the right temporal horn. MRI: Magnetic resonance imaging

Click here to view

Discussion

MOGAD has heterogenous clinical and imaging presentations, and encephalitis is an important phenotype.^[3] Unilateral CCE is a rare finding of anti-MOG, which was first reported by Ogawa et al.^[4] The authors described four cases who had seizures, MOG-IgG positivity, and unilateral cortical hyperintensities on T2-FLAIR sequences of MRI. Its incidence is extremely low compared to stroke.^[7] The imaging features of anti-MOG-associated encephalitis with seizures were named as FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES) by Budhram et al.;^[8] the common clinical manifestations were seizures, headache, fever, and cortical symptoms in the “FLAMES” location.^[8]

The patient of this case was presented with the typical clinical manifestations of anti-MOG-associated CCE, including headache, fever, and seizure. In addition, diagnosis of anti-MOG-associated CCE could be confirmed with hyperintense cortical lesions on T2-FLAIR and a high titer of anti-MOG antibody from serum and CSF. However, some unique clinical features were noted in this case, compared to those in the past. In previously reported cases, most patients responded well to high-dose glucocorticoids and recovered completely with no relapse.^{[4],[8],[9],[10],[11],[12],[13],[14],[15]} A few cases with relapse^{[3],[16],[17],[18],[19]} typically presented with optic neuritis, ADEM, longitudinally extensive transverse myelitis, or brainstem syndromes. Interestingly, there was a relapse after a high-dose glucocorticoid therapy in this case and lesions were found in the ipsilateral cerebral cortex. Based on previous studies, a few possibilities responsible for these unique clinical features were considered: (1) a rapid tapering or withdrawal of high-dose steroids,^[6] (2) high antibody levels, and (3) and/or persistent seropositivity.^[20],[21] In fact, studies had shown that a long-term immunotherapy was associated with a reduction of relapse rate in patients with MOGAD, which advocated the need of immunosuppressants.^[22],[23] Unfortunately, the patient of this case did not agree with MOG antibody titer again. The treatment was guided symptomatically and mainly based on the imaging study changes, which was the limitation of this case study.

In the past reports, abnormal signals on brain MRI disappeared without residual lesions in most treated patients. The patient of this case, on the other hand, developed cognitive impairment associated with global cerebral atrophy after two episodes of unilateral cortical encephalitis, which had rarely occurred from adult patients with anti-MOG-associated CCE. Armangue et al.^[24] conducted a multicenter observational study and described a 9-year-old boy with a clinical presentation of cortical encephalitis. His MRI initially became normal after treatment. However, he developed a relapse with clinical and radiographic features similar to the initial episode. Severe cortical atrophy was noted from a follow-up MRI 6 months later, and this was associated with poor recovery. In a retrospective study, Wang et al.^[3] described 18 patients with anti-MOG-associated encephalitis. Two of these patients had temporal lobe atrophy and another patient with faint residual white matter lesions. The rest showed complete clinical resolution after being treated. It seems to be reasonable to speculate that the pathogenesis of anti-MOG-associated encephalitis is immune mediated or autoantibody mediated based on the fact that persistent anti-MOG antibodies are associated with chronic damage to the cerebral cortical cells. Moreover, the patient of this was relatively older than other reported patients with anti-MOG-associated encephalitis.

The relationship between CCE and MOG antibodies is not well understood. Brain biopsy is hardly performed to assess anti-MOG-associated CCE. Lymphocytic infiltration has been observed in the subarachnoid space, brain parenchyma, and perivascular regions, and demyelination is largely absent.^[25] Oligodendrocytes are notably present in the subcortical white matter, and myelinated oligodendrocytes are also found in the cortical gray matter for axonal conduction. These histological findings may be associated with the cortical symptoms in MOGAD.^[26] When the white matter is damaged, oligodendrocytes and other cells in the neurovascular unit can mend damage to the white matter and restore brain function ensuing neural injury.^[27] Finally, it is possible that MOG antibody may not be directly involved in the unilateral CCE. A separate autoimmune entity, such as NMOSD coexisting with MOG antibody, may be responsible for the encephalitis.

Conclusion

MOGAD is often presented with CCE. When anti-MOG-associated CCE is suspected, especially with headaches, fever, and seizures, serum should be analyzed for the presence of MOG-ab at the earliest for a timely treatment. Anti-MOG-associated CCE can cause global cerebral atrophy after treatment and can relapse as other MOGADs. The standard steroid therapy is required for MOGAD with unilateral cortical encephalitis; immunosuppressants may be necessary with gradual tapering to prevent recurrence. Finally, MOGAD is a newly discovered brain disease, and cortex encephalitis is one of the subtypes. There appear to be various subtypes to be discovered, and the unknown pathogenesis needs a lot of laboratory work.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

Dr. Yuchuan Ding is an Associate Editor, Dr. Xiaokun Geng is an Editorial Board member of Brain Circulation. The article was subject to the journal's standard procedures, with peer review handled independently of them and their research groups.

References

1.	Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15:134.
2.	Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021;20:762-72.
3.	Wang L, ZhangBao J, Zhou L, Zhang Y, Li H, Li Y, et al. Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: A single-center cohort study in Shanghai, China. Eur J Neurol 2019;26:168-74.
4.	Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017;4:e322.
5.	Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain 2017;140:3128-38.
6.	Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VS, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127-37.
7.	Leng T, Xiong ZG. Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges. Brain Circ 2019;5:8-11. [PUBMED] [Full text]
8.	Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): Characterization of a distinct clinico-radiographic syndrome. J Neurol 2019;266:2481-7.
9.	Jain K, Cherian A, Divya KP, Rajalakshmi P, Thomas B, Nandana J. FLAMES: A novel burning entity in MOG IgG associated disease. Mult Scler Relat Disord 2021;49:102759.
10.	Tao R, Qin C, Chen M, Yu HH, Wu LJ, Bu BT, et al. Unilateral cerebral cortical encephalitis with epilepsy: A possible special phenotype of MOG antibody-associated disorders. Int J Neurosci 2020;130:1161-5.
11.	Katsuse K, Shimizu G, Saito Sato N, Hatano K, Yagi S, Kimura T, et al. Epilepsia partialis continua as an early sign of anti-myelin oligodendrocyte glycoprotein antibody-positive encephalitis. Intern Med 2020;59:1445-9.
12.	Tian F, Liu X, Yang C, Wang B, Song Z, Zhang Y. MOG antibody-positive cerebral cortical encephalitis: Two case reports and literature review. Int J Dev Neurosci 2021;81:342-51.
13.	Wang YF, Liu XW, Lin JM, Liang JY, Zhao XH, Wang SJ. The clinical features of FLAIR-hyperintense lesions in Anti-MOG antibody associated cerebral cortical encephalitis with seizures: Case reports and literature review. Front Immunol 2021;12:582768.
14.	Fujimori J, Ogawa R, Murata T, Jin K, Yazawa Y, Nakashima I. Unilateral chronic pulsatile headache as the single manifestation of anti-MOG antibody-associated unilateral cerebral cortical encephalitis. J Neuroimmunol 2020;346:577322.
15.	Adachi H, Ide Y, Takahashi T, Yoneda Y, Kageyama Y. Cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein (MOG) antibody. Rinsho Shinkeigaku 2018;58:767-70.
16.	Sugimoto T, Ishibashi H, Hayashi M, Tachiyama K, Fujii H, Kaneko K, et al. A case of anti-MOG antibody-positive unilaterally dominant meningoencephalitis followed by longitudinally extensive transverse myelitis. Mult Scler Relat Disord 2018;25:128-30.
17.	Zhou L, ZhangBao J, Li H, Li X, Huang Y, Wang M, et al. Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Mult Scler Relat Disord 2017;18:90-2.
18.	Fujimori J, Takai Y, Nakashima I, Sato DK, Takahashi T, Kaneko K, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 2017;88:534-6.
19.	Fukushima N, Suzuki M, Ogawa R, Hayashi K, Takanashi JI, Ohashi T. A case of anti-MOG antibody-positive multiphasic disseminated encephalomyelitis co-occurring with unilateral cerebral cortical encephalitis. Rinsho Shinkeigaku 2017;57:723-8.
20.	Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology 2018;90:e1858-69.
21.	Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler 2019;25:1907-14.
22.	Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020;95:e111-20.
23.	Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018;75:478-87.
24.	Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: A multicentre observational study. Lancet Neurol 2020;19:234-46.
25.	Ikeda T, Yamada K, Ogawa R, Takai Y, Kaneko K, Misu T, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: A case report. J Neurol Sci 2018;392:113-5.
26.	Ramanathan S, O'grady GL, Malone S, Spooner CG, Brown DA, Gill D, et al. Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol 2019;61:610-4.
27.	Hamanaka G, Ohtomo R, Takase H, Lok J, Arai K. White-matter repair: Interaction between oligodendrocytes and the neurovascular unit. Brain Circ 2018;4:118-23. [PUBMED] [Full text]